Lupin Introduces Triple-Combination Inhaler for COPD

Pharmaceutical major

Limited has launched Formoflo-G MDI in India following approval from the Drug Controller General of India (DCGI). The company describes it as the world's first fixed-dose triple-combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD). Key Product Highlights Brand: Formoflo-G MDI Combination: Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate Dosage: Fixed-dose formulation designed for twice-daily use Indication: Long-term management of moderate to severe COPD in appropriate patients The launch strengthens Lupin’s respiratory-care portfolio by bringing three established medicines together in a single inhaler. The company aims to expand access to differentiated respiratory therapies and address unmet treatment needs. Lupin Managing Director Nilesh Gupta and India Region Formulations President Rajeev Sibal highlighted the launch as an important step in the company's commitment to respiratory-care innovation and improved patient outcomes. Market Focus: Investors may monitor product uptake, prescription demand and the launch's contribution to Lupin's respiratory segment growth. #Lupin #LupinLimited #PharmaNews #PharmaceuticalSector #COPD #RespiratoryCare #HealthcareInnovation #PharmaStocks #StockMarketNews #IndianStockMarket #NiveshResearch Disclaimer: Investment in securities market are subject to market risks. Read all related documents carefully before investing. This content is for informational purposes only and is not a buy or sell recommendation.